ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 765 USD | -.--% |
|
-.--% | -.--% |
| 30/05 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
| 30/05 | Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs | RE |
| Sales 2024 * | 42.98B 3,585B | Sales 2025 * | 52.62B 4,389B | Capitalization | 739B 61,611B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 995B | Net income 2025 * | 16.55B 1,381B | EV / Sales 2024 * | 17.6 x |
| Net Debt 2024 * | 18.07B 1,507B | Net Debt 2025 * | 15B 1,251B | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
44.2
x | Employees | 43,000 |
| Yield 2024 * |
0.63% | Yield 2025 * |
0.73% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| Current month | -6.24% | ||
| 1 month | +0.62% |
1 week
765.00
817.60
1 month
760.30817.60
Current year
760.30817.60
1 year
760.30817.60
3 years
760.30817.60
5 years
760.30817.60
10 years
760.30817.60
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 815.9 | +6.65% |
| 30/24/30 | 765 | -.--% |
| 29/24/29 | 765 | -.--% |
| 28/24/28 | 765 | -.--% |
| 27/24/27 | 765 | -.--% |
End-of-day quote Lima, May 30, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
